Australia Daily Briefing

CSL Limited closed at $341.93 (+2.11%), its strongest single-day performance in recent weeks, as the healthcare sector outperformed in a global risk-on session. CSL's core biologics business — plasma therapies and vaccines — is a structural compounder with minimal China demand exposure, making it a preferred ASX defensive-growth name when macro uncertainty is elevated. The stock's +2.11% on a +1.18% index day represents meaningful alpha generation. With the RBA keeping rates elevated, superannuation funds have been rotating into high-quality domestics with genuine earnings visibility — CSL fits that profile precisely. Thursday catalyst watch: any US FDA approval or clinical readout for CSL Behring would add further legs to this move.

Newmont (NEM) +2.06% to $125.16 tracked gold's global bid, supported by Iran-US Strait of Hormuz tension and Treasury yield volatility that activated both gold-as-safe-haven and gold-as-inflation-hedge simultaneously. When both rationales run in tandem, Australian gold miners get double the torque — and ASX's heavy mining weighting (~25% of ASX 200) means precious-metal moves translate into meaningful index tailwinds. BHP +0.66% and RIO +0.87% added base-metals support, though iron ore prices were a secondary driver today (those gains were tracking gold, not Chinese steel demand). A new high-grade Evergreen discovery at Australian Gold and Copper's South Cobar Project adds domestic junior exploration narrative to the precious metals theme.

Macquarie Group (MQBKY) fell 2.08% to $175, dragging the Banking sector negative in an otherwise constructive session. With Macquarie up 24% in recent months, today's selloff looks like profit-taking after an extended run rather than fundamental deterioration. But the distinction matters: as a global investment bank, Macquarie's revenue is more correlated with global M&A activity and infrastructure deal flow than with domestic Australian interest rates. Its underperformance relative to the Big Four (CBA, NAB, WBC, ANZ) makes structural sense on a BoC-hold-adjacent day — the pure NIM-expansion trade rewards simple banking models, not Macquarie's complex asset-management structure. The question is whether this 2% dip attracts any buying Thursday, or whether 'still a good buy at $175?' has a genuinely uncertain answer for growth-oriented institutional desks.